Phase 2/3 trial of Izalontamab Brengitecan, EGFR/HER3 bispecific ADC with topoisomerase inhibition

This randomized, open-label study compares iza-bren monotherapy versus physician’s choice in first-line metastatic triple-negative or ER-low, HER2-negative breast cancer patients ineligible for anti-PD(L)1 or endocrine therapies. Sponsored by Bristol-Myers Squibb, the trial evaluates safety and efficacy of a bispecific ADC targeting EGFR and HER3 with a topoisomerase inhibitor payload.